Work

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

Year: 2022

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood-2022-157149

Authors: Jennifer N. Brudno, Jeremiah Karrs, Danielle Natrakul, Nisha Patel, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven Highfill, Norris Lam, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Institutes of Health Clinical Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310119590

FWCI: 0.273

Cites:

Cited by: 3

Related to: 10